Add Inspra™ Add life 1,2

The standard of care for protection in post-MI heart failure2
ESC-recommended for HFrEF (NYHA Class II–IV)3,8

Proven efficacy in clinical care1,2,4–6:

- Adding Inspra to standard therapy1 significantly reduced the risk of CV mortality or HF hospitalization in CHF (NYHA Class II) by 37% compared with standard therapy alone11.
- The incidence of hyperkalemia was improved when an MRA, including Inspra, was used in combination with an ARNI or SGLT2 inhibitor4–6.
- Inspra significantly reduced the risk of all-cause mortality in post-MI HF patients by 15% compared with placebo11.


INSPIRA ADVERSE EFFECTS PRESCRIBING INFORMATION: 1. Trade Name: INSPIRA. Indicated as an adjunct to standard therapy to reduce the risk of cardiovascular (CV) mortality and hospitalization for CHF in patients with New York Heart Association (NYHA) Class II, III, or IV heart failure. 2. Approved for use in CHF. Gastrointestinal (GI) bleeding, increase in serum potassium, edema, and hyperkalemia are common side effects. 3. Risks include: sodium retention, hypokalemia, hyperkalemia, edema, orthostatic hypotension, and Gastrointestinal (GI) bleeding. 4. Insomnia may occur and may be treated with doses of 25 mg or lower. 5. Dizziness may occur and may be treated with doses of 25 mg or lower. 6. Anemia may occur and may be treated with doses of 25 mg or lower. 7. Interactions: Inspira should not be used with strong inhibitors of CYP3A (e.g., ritonavir, indinavir, saquinavir, and amprenavir) and strong inducers of CYP2C9 (e.g., phenytoin, carbamazepine, and rifampin). 8. Monitoring: potassium levels should be monitored at baseline and weekly during treatment. 9. Pregnancy: Inspira is not recommended for use during pregnancy. 10. Safety and effectiveness in children have not been established.

Viatris Healthcare Hong Kong Limited
Shatin 2401-07 & 12, 24/F, One Island East,
18 Westlands Road, Quarry Bay, Hong Kong
Tel: +852 2290 7100 | Fax: +852 2673 9018 | Website: www.viatris.com
© 2022 Viatris – All Rights Reserved

INSPIRA PRESCRIBING INFORMATION IS AVAILABLE UPON REQUEST.
Table of Contents

Welcome Message 2
Organizing Committee, Scientific Committee and Faculty 3
Forum Information 10
General Information about Hong Kong 12
Scientific Program 14
Biography of Guest of Honour 19
Biography of Keynote Speaker 20
Biography of Distinguished Professorial Lecturer 21
Biography of Overseas Speakers 21
Biography of Hong Kong Speakers 34
Map & Exhibition 39
Acknowledgments 40
Welcome Message

After a two-year hiatus, the Asia Pacific Advanced Heart Failure Forum (APAHFF) has returned with a mission to deliver yet another highly educational scientific program to continue its tradition of bringing leading-edge science and clinical knowledge to the region.

This year, we are delighted to have the opportunity to co-develop HFSA-APAHFF 2022 Meeting with the Heart Failure Society of America (HFSA) and the Journal of Cardiac Failure. HFSA is the largest professional organization in North America that is dedicated to all aspects of heart failure.

The first half of the scientific program features single-track HFSA Lectures given by The Society's distinguished faculty. Presentations in the second half of the program will be given by mostly speakers from the Asia Pacific region in concurrent sessions, following a European Heart Journal Special Session led by academicians from Europe. We are confident that you will enjoy the contents of this year's meeting presented by a diverse group of experts who are thought leaders in American, European and Asian cardiology, cardiac surgery, and different heart failure-related disciplines of medicine and clinical science. Attendees will receive a complimentary copy of the day's presentations or have free online access to the contents.

Due to the ongoing pandemic, the meeting will be conducted in a hybrid (on-site and online) format to accommodate your preferred mode of participation. We encourage everyone to share their thoughts, comments and practical experiences during Roundtables at the end of each session.

Thank you for your interest. We hope you will enjoy the HFSA-APAHFF 2022 Meeting!

Erik Fung
MD, PhD, FACC
Co-Chair, APAHFF Organizing Committee
Assistant Professor, Division of Cardiology
Department of Medicine & Therapeutics
Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

W. H. Wilson Tang
MD, FACC, FAHA, FHFS
Co-Chair, APAHFF Organizing Committee
Professor, Division of Cardiovascular Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University, Cleveland, Ohio, USA
Organizing Committee & Faculty

Co-Chair
Erik Fung

Co-Chair
W. H. Wilson Tang

Senior Scientific Advisor
Joseph Y.S. Chan

Scientific Committee (by alphabetical order)
Gary C. P. Chan  Yu Ho Chan  Mário Évora  Roger S. Y. Foo
Kevin K. H. Kam  Edmund M. Lau  Alex P. W. Lee  Goro Matsumiya
Toi Meng Mok  Mónica Pon  Dao Wen Wang  Wei-Ting Wang
Michael K. L. Wong  Timothy C. Wong  Eugene B. Wu  Bryan P. Yan

Guest of Honour
Hong Fung
CEO, CUHK Medical Centre
Professor of Practice in Health Services Management,
Jockey Club School of Public Health and Primary Care,
Faculty of Medicine, The Chinese University of Hong Kong
Hong Kong SAR, China

Keynote Speaker
James C. Fang
Chief of Cardiovascular Medicine
University of Utah School of Medicine
Salt Lake City, Utah, USA

Distinguished Professorial Lecturer
Cecilia W. Y. Lo
Professor and F. Sargent Cheever Endowed Chair
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, USA
### Overseas Speakers (by alphabetical order)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antoni Bayés-Genís</td>
<td>Hospital Universitari Germans Trias i Pujol</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>Chiara Bucciarelli-Ducci</td>
<td>Royal Brompton &amp; Harefield Hospitals</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Yang Hyun Cho</td>
<td>Samsung Medical Center</td>
<td>Seoul, South Korea</td>
</tr>
<tr>
<td>Jennifer A. Cowger</td>
<td>Henry Ford Hospital</td>
<td>Detroit, Michigan, USA</td>
</tr>
<tr>
<td>Filippo Crea</td>
<td>Università Cattolica del Sacro Cuore</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>Mark H. Drazner</td>
<td>UT Southwestern Medical Center</td>
<td>Dallas, Texas, USA</td>
</tr>
<tr>
<td>James C. Fang</td>
<td>University of Utah Health</td>
<td>Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td>Gregg C. Fonarow</td>
<td>Ronald Reagan UCLA Medical Center</td>
<td>Los Angeles, California, USA</td>
</tr>
<tr>
<td>Michael W. Fong</td>
<td>Keck Medical Center of USC</td>
<td>Los Angeles, California, USA</td>
</tr>
<tr>
<td>Marjorie W. Y. Foo</td>
<td>Singapore General Hospital</td>
<td>Singapore</td>
</tr>
<tr>
<td>Navin K. Kapur</td>
<td>Tufts Medical Center</td>
<td>Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>Hiroki Kohno</td>
<td>Chiba University Hospital</td>
<td>Chiba, Japan</td>
</tr>
<tr>
<td>Edmund M. Lau</td>
<td>Royal Prince Alfred Hospital</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>Cecilia W. Y. Lo</td>
<td>University of Pittsburgh School of Medicine</td>
<td>Pittsburgh, Pennsylvania, USA</td>
</tr>
<tr>
<td>Peter S. Macdonald</td>
<td>St Vincent's Hospital</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>Mandeep R. Mehra</td>
<td>Brigham and Women's Hospital</td>
<td>Boston, Massachusetts, USA</td>
</tr>
</tbody>
</table>
Overseas Speakers (by alphabetical order)

Shirlyn H. S. Neo  
National Cancer Centre  
Singapore

Sunita Puri  
Keck Hospital of USC & Norris-Cotton Cancer Center  
University of Southern California  
Los Angeles, California, USA

Sandeep Seth  
All India Institute of Medical Sciences  
New Delhi, India

Ching Hui Sia  
National University Heart Centre  
National University of Singapore  
Singapore

Lynne Warner Stevenson  
Vanderbilt University School of Medicine  
Vanderbilt University Medical Center  
Nashville, Tennessee, USA

Nancy K. Sweitzer  
University of Arizona Sarver Heart Center  
The University of Arizona College of Medicine  
Tucson, Arizona, USA

Yuichi Tamura  
International University of Health and Welfare  
Mita Hospital  
Tokyo, Japan

W. H. Wilson Tang  
Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University  
Cleveland, Ohio, USA

Nir Y. Uriel  
Columbia University Vagelos College of Physicians  
Columbia University Irving Medical Center  
New York, New York, USA

Narittaya Varothai  
Bumrungrad International Hospital  
Bangkok, Thailand

Yan Wang  
Tongji Medical College  
Huazhong University of Science and Technology  
Wuhan, People’s Republic of China

Dao Wen Wang  
Tongji Medical College  
Huazhong University of Science and Technology  
Wuhan, People’s Republic of China

Tee Joo Yeo  
National University Heart Centre  
Singapore
Local Speakers (by alphabetical order)

Ngai-Yin Chan
Princess Margaret Hospital & North Lantau Hospital
Hong Kong SAR, China

Eva Y. W. Chun
CUHK Medical Centre
Hong Kong SAR, China

Erik Fung
The Chinese University of Hong Kong
Prince of Wales Hospital and CUHK Medical Centre
Hong Kong SAR, China

S. H. Jo Jo Hai
University of Hong Kong
Queen Mary Hospital
Hong Kong SAR, China

Cally K. L. Ho
Queen Mary Hospital
Hong Kong SAR, China

Andrea O. Y. Luk
The Chinese University of Hong Kong
Prince of Wales Hospital
Hong Kong SAR, China

Kin Shing Lun
Hong Kong Children’s Hospital
Hong Kong SAR, China

Ronald C. W. Ma
The Chinese University of Hong Kong
Prince of Wales Hospital
Hong Kong SAR, China

David C. W. Siu
The University of Hong Kong
Queen Mary Hospital
Hong Kong SAR, China

Michael K. L. Wong
Grantham Hospital
Hong Kong SAR, China
EMPOWERED BY YOU
POWERED BY Jardiance®
(empagliflozin)

Proven Efficacy
- 25% RRR in CV death or HHF on top of standard of care
- Protected the kidneys by slowing the decline in kidney function over time

Demonstrated Safety and Tolerability Profile

Simple Dosing
Oral, once-daily dose with no titration

REFERENCES
1. Jardiance® Abbreviated Prescribing Information (API) JARD-01
2. Jardiance Hong Kong Prescribing Information

FOOTNOTES
1. Adult patients with chronic heart failure (NYHA class III, or IV) and reduced ejection fraction (LVEF ≤ 40%) [5, 12]
2. When JARDIANCE is used in combination with a sulfonylurea or with insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia [7].
3. In the EMPEROR-Reduced trial, a randomized, double-blind, parallel-group, placebo-controlled study of 3,992 patients with HFrEF, the efficacy and safety of JARDIANCE 10 mg (in HFrEF) was evaluated vs placebo (in HFrEF). The primary composite endpoint in the EMPEROR-Reduced trial was a composite of CV death or HFH, analyzed as time to the first event. Patients treated with JARDIANCE experienced a 25% risk reduction in this endpoint (10.4% in the JARDIANCE group vs 13.9% in the placebo group). [5, 12]
4. Standard of care: All patients received appropriate treatments for heart failure, including diuretics, inhibitors of the renin-angiotensin system and nephrin, beta blockers, renin-angiotensin receptor and, when indicated, cardiac denervating agents.
5. The rate of the decline in LVEF was a prespecified secondary outcome of the EMPEROR-Reduced trial.
7. Asset. Heart Association: ACC/AHA/AHA guidelines for the limitation and resolution of heart failure, 2011; Advanced aortic valve surgery; Atrial fibrillation; and the use of the Jardiance drug.
**Moderators (by alphabetical order)**

Glenn Rose Advincula (Manila, Philippines)
Tung Wai AuYeung (Hong Kong SAR)
Gary C. P. Chan (Hong Kong SAR)
Juliana C. N. Chan (Hong Kong SAR)
Ngai-Yin Chan (Hong Kong SAR)
Yu Ho Chan (Hong Kong SAR)
Chi-Ming Chow (Toronto, Ontario, Canada)
Ka Lung Chui (Hong Kong SAR)
Lucky R. Cuenza (Quezon City, Philippines)
Mário Évora (Macau SAR)
Michael W. Fong (Los Angeles, USA)
Roger S. Y. Foo (Singapore)
Erik Fung (Hong Kong SAR)
Ling Ling Ip (Hong Kong SAR)
Kevin K. H. Kam (Hong Kong SAR)
Ganesan Karthikeyan (New Delhi, India)
Alice P. S. Kong (Hong Kong SAR)
Edmund M. Lau (Sydney, Australia)
Godwin T. C. Leung (Hong Kong SAR)
Y. S. Archie Lo (Hong Kong SAR)
Raymond S. K. Lo (Hong Kong SAR)
Goro Matsumiya (Chiba, Japan)
Toi Meng Mok (Macau SAR)
Mónica Pon (Macau SAR)
Cumaraswamy Sivathasan (Singapore)
Yuchi Tamura (Tokyo, Japan)
W. H. Wilson Tang (Cleveland, OH, USA)
G. M. Tan (Hong Kong SAR)
Steven Tsui (Cambridge, UK)
Narittaya Varothai (Bangkok, Thailand)
Wei-Ting Wang (Taipei, Taiwan)
Timothy C. Wong (Pittsburgh, PA, USA)
Eugene B. Wu (Hong Kong SAR)
Huei Yaw Wu (Singapore)
Bryan P. Yan (Hong Kong SAR)
Zaheer Yousef (Cardiff, UK)
Cheuk-Man Yu (Hong Kong SAR)
FORXIGA is now A CLASS 1A FIRST-LINE THERAPY for all HFrEF patients in ESC 2021 HF guideline**

**Consistent Efficacy & Simple and well tolerated**

- Comparable rate of volume depletion, renal dysfunction, and hypoglycemia vs placebo
- 10 mg once daily
- No dose titration
- Initiate treatment if GFR ≥25 mL/min
Forum Information

Event Date May 7, 2022 (Saturday, GMT+8, Hong Kong)

Venue Charles K. Kao Auditorium, Hong Kong Science Park, Shatin, New Territories, Hong Kong SAR, China

Organizer Division of Cardiology, Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong

Format Hybrid mode (virtual broadcast and in-person attendance)

Letter of Invitation
The Organizing Committee is pleased to provide letters of invitation to facilitate delegates’ travel and visa arrangements upon request.

Language
The official language of the meeting is English. There will be no simultaneous translation.

Registration
Please complete the registration form and return it with the appropriate fee via email to the Secretariat of the HFSA-APAHFF 2022 Meeting.
Email: APAHFF@cuhk.edu.hk

Registered delegates will be entitled to:
Program Book and delegate’s kit
Access to all scientific sessions on May 7, 2022
Access to exhibition areas
On-site coffee/tea break and lunch on May 7, 2022 (in-person only)

Certificate of Attendance
A certificate of attendance will be issued to registered delegates.

Trade Exhibition
Pharmaceutical, medical equipment and device companies, and book vendors will be exhibiting products and product information at the Forum. These are available for viewing throughout the day.
Professional Accreditations
For USA: ACCME credits for continuing medical education will be available to attendees.
For Hong Kong: Continuing Medical Education (CME), Continuing Nursing Education (CNE) and Central Pharmacy Unit (CEU) credits will be available from the relevant professional institutions.
Please note that credits may not be transferrable to overseas accrediting organizations.

Disclaimer
The Organizing Committee reserves the right to make changes to the schedule without prior notice.

Secretariat
APAHFF Secretariat, CUHK
Room 508, Li Ka Shing Medical Sciences Building
Prince of Wales Hospital
30-32 Ngan Shing Street
Shatin, New Territories
Hong Kong SAR, China
Email: APAHFF@cuhk.edu.hk
General Information about Hong Kong

Time
Hong Kong time is 8 hours ahead of the Greenwich Mean Time (GMT+8).

Climate
Hong Kong enjoys a subtropical climate with distinct seasons. Temperature in May usually ranges from 25°C to 32°C (77°F to 90°F) with average humidity of about 70%. For the latest weather information, please visit: https://www.hko.gov.hk/en/index.html.

Language
Cantonese and English are the official languages of Hong Kong. All road signs and most menus and tourist publications are bilingual. Cantonese is the predominant Chinese dialect spoken in Hong Kong. English and Putonghua may be considered additional working languages.

Currency, Office and Bank Hours
The Hong Kong Dollar (HKD) is the local currency. It is pegged to the US Dollar at a rate of HKD $7.78 to USD $1. Travellers’ cheques in foreign currencies may be exchanged for cash in HKD at banks, hotels or currency exchange stores. Credit and debit cards (VISA, MasterCard, UnionPay, American Express, JCB, JETCO, Maestro, Cirrus etc.) are widely accepted in hotels, shops and restaurants. Banks open from 09:00 to 17:00 while offices generally open from 09:00 to 17:00 on Mondays to Fridays.

Electricity
The standard electrical voltage is 220 volts AC, 50 Hz. Most electrical outlets in Hong Kong take a three-rectangular-pronged plug.

Transportation
The major means of transport in Hong Kong include the Mass Transport Railway (trains, subway, light rail etc.), buses, taxis, and other road transport. For further details, please visit: https://www.td.gov.hk/tc/home/index.html.

Telecommunication
Internet and international direct dialling are easily accessible in Hong Kong. The mobile (cellular) phone networks and Wi-Fi access are widely available. Most hotels have internet access for laptop computer users, and some may offer desktop work stations and business offices. Wireless broadband service is commonly available at major shopping malls and coffee shops.

For further information, please visit the Hong Kong Tourism Board at: https://www.discoverhongkong.com/eng/index.html.
**Increasing FREE WATER CLEARANCE with SAMSCA®**

**SAMSCA® is effective at raising serum Na⁺ in HF patients over 30 days**

Pooled analysis of SALT-1 and SALT-2, mean change from baseline vs. placebo (P<0.0001)*

<table>
<thead>
<tr>
<th>Day 4</th>
<th>Day 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5 ± 0.5 mEq/L</td>
<td>6.6 ± 2.4 mEq/L</td>
</tr>
</tbody>
</table>

**SAMSCA® has a significant effect on fluid balance in HF patients**

Mean net fluid balance at day 1 in patients with baseline serum Na⁺ <135mEq/L (p=0.0027)*

**SAMSCA® -1860mL vs. Placebo -787mL**

**Indication**

SAMSCA® is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <135mEq/L), or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction, including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).

**Reference**

2. SAMSCA® (tolvaptan) Hong Kong Prescribing Information revised Mar 2019.

HF: Heart failure; Na+: Sodium

**Abbreviated Prescribing Information**

SAMSCA® (tolvaptan) 15 mg and 30 mg tablets. **INDICATION** Treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <135 mEq/L), or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction, including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH). **WARNING** Tolvaptan should be used in the context of a management plan that includes fluid restriction and evaluation of the cause of hyponatremia. The high sodium content of the tablets can cause major (≥5mEq/L) increase in sodium concentration. **CONTRAINDICATIONS** Acute renal failure, dehydration, hypernatremia, hypovolaemia, hypotension, hypotensive states, and hyponatremia due to hypoaldosteronism.**ADVERSE REACTIONS** Tolvaptan, given on an as-needed basis, is generally well-tolerated. The most commonly reported adverse event was nausea.

**Precautions**

1. Sodium should be measured at least hourly during the first 24 hours of therapy. пациентов с гипернедержанием воды или гипохлоремией, пациентов с низким уровнем альдостерона, пациентов с гипоальдостеронизмом, **ADVERSE REACTIONS** Tolvaptan, given on an as-needed basis, is generally well-tolerated. The most commonly reported adverse event was nausea.

**Indications**

1. Patients with hypervolemic or euvolemic hyponatremia (serum sodium <135 mEq/L), or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction, including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).

**Precautions**

1. Sodium should be measured at least hourly during the first 24 hours of therapy. **CONTRAINDICATIONS** Acute renal failure, dehydration, hypernatremia, hypovolaemia, hypotension, hypotensive states, and hyponatremia due to hypoaldosteronism. **ADVERSE REACTIONS** Tolvaptan, given on an as-needed basis, is generally well-tolerated. The most commonly reported adverse event was nausea.

**Indications**

1. Patients with hypervolemic or euvolemic hyponatremia (serum sodium <135 mEq/L), or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction, including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).

**Precautions**

1. Sodium should be measured at least hourly during the first 24 hours of therapy. **CONTRAINDICATIONS** Acute renal failure, dehydration, hypernatremia, hypovolaemia, hypotension, hypotensive states, and hyponatremia due to hypoaldosteronism. **ADVERSE REACTIONS** Tolvaptan, given on an as-needed basis, is generally well-tolerated. The most commonly reported adverse event was nausea.

**Indications**

1. Patients with hypervolemic or euvolemic hyponatremia (serum sodium <135 mEq/L), or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction, including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).

**Precautions**

1. Sodium should be measured at least hourly during the first 24 hours of therapy. **CONTRAINDICATIONS** Acute renal failure, dehydration, hypernatremia, hypovolaemia, hypotension, hypotensive states, and hyponatremia due to hypoaldosteronism. **ADVERSE REACTIONS** Tolvaptan, given on an as-needed basis, is generally well-tolerated. The most commonly reported adverse event was nausea.
# HFSA-APAHFF 2022

**Venue:** Charles K.Kao Auditorium, Hong Kong Science Park, Shatin, New Territories, Hong Kong

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 08:50</td>
<td>Welcome and Introduction</td>
<td>Hong Fung, CEO, CUHK Medical Centre, Hong Kong SAR</td>
</tr>
<tr>
<td>09:05 - 09:30</td>
<td>HFpEF Therapy in 2022: What Drug and Why?</td>
<td>James C. Fang (Salt Lake City, UT, USA)</td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td>Get-With-The-Guidelines &amp; GDMT: Why It Matters</td>
<td>Gregg C. Fonarow (Los Angeles, CA, USA)</td>
</tr>
<tr>
<td>09:50 - 10:10</td>
<td>Cardiovascular and Heart Failure Management of COVID-19: The New York Experience</td>
<td>Nir Uriel (New York, NY, USA)</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>The Clinical Examination in Patients with Heart Failure: New Insights</td>
<td>Mark H. Drazner (Dallas, TX, USA)</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>Novel Medical Therapies for Heart Failure and Cardiomyopathies</td>
<td>W. H. Wilson Tang (Cleveland, OH, USA)</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>The Future of Mechanical Circulatory Support</td>
<td>Mandeep R. Mehra (Boston, MA, USA)</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>Pulmonary Decongestion in Heart Failure: Who Are the High-Risk Patients</td>
<td>Lynne W. Stevenson (Nashville, TN, USA)</td>
</tr>
</tbody>
</table>
### Session IIC: HFSA Lectures

**Moderators:** Eugene B. Wu (Hong Kong), Yu Ho Chan (Hong Kong), Wei-Ting Wang (Taipei)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:50</td>
<td>Advances in Percutaneous VAD Technology</td>
<td>Navin K. Kapur</td>
<td>Boston, MA, USA</td>
</tr>
<tr>
<td>11:50 - 12:10</td>
<td>State-of-The-Art in Invasive Hemodynamics</td>
<td>Nancy K. Sweitzer</td>
<td>Tucson, AZ, USA</td>
</tr>
<tr>
<td>12:10 - 12:30</td>
<td>Bridging Patients Safely from VAD to Transplant</td>
<td>Jennifer A. Cowger</td>
<td>Detroit, MI, USA</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td><strong>Lunch Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Distinguished Professorial Lecture</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>Mechanisms of Heart Failure in Hypoplastic Left Heart Syndrome</td>
<td>Cecilia W. Y. Lo</td>
<td>Pittsburgh, PA, USA</td>
</tr>
<tr>
<td>13:50 - 15:00</td>
<td><strong>European Heart Journal Special Session</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:20</td>
<td>Cardiac Magnetic Resonance Imaging in Heart Failure</td>
<td>Chiara Buccarelli-Ducci</td>
<td>London, UK</td>
</tr>
<tr>
<td>14:20 - 14:35</td>
<td>Circulating Biomarkers for Heart Failure: <em>quo vadis?</em></td>
<td>Antoni Bayés-Genís</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td>Multimodality Cardiovascular Imaging in the Investigation of Decompensated Heart Failure in Patients with Adult Congenital Heart Disease</td>
<td>Kin Shing Lun</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td><strong>Roundtable Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session I</td>
<td>Session II</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>------------</td>
<td></td>
</tr>
</tbody>
</table>
| 15:00 - 15:40   | SESSION III: Cardiac Transplantation in the Asia Pacific Region  
Moderators: Glenn Rose Advincula (Philippines), Steven Tsui (Cambridge, UK) | SESSION IV: Cardiac Electrophysiology  
Moderators: Gary C. P. Chan (Hong Kong), Cheuk-Man Yu (Hong Kong) |
| 15:00 - 15:10   | Machine Perfusion of Donor Hearts  
Peter S. Macdonald (Sydney, Australia) | Atrial Fibrillation in Heart Failure: A Case for Prevention  
Ching Hui Sia (Singapore) |
| 15:10 - 15:20   | Review and Updates on Heart Transplant in South Korea: Impact of Administrative Systems Change on the Frontline  
Yang Hyun Cho (S. Korea) | AF Ablation for Patients with Heart Failure  
Yan Wang (Wuhan, China) |
| 15:20 - 15:30   | Successes and Challenges of Heart Transplantation in India Over the Past Two Decades  
Sandeep Seth (New Delhi, India) | Cardiac Contractility Modulation for Advanced Heart Failure  
Jo Jo Hai (Hong Kong) |
| 15:30 - 15:40   | Roundtable Discussion | Roundtable Discussion |
| 15:40 - 16:20   | SESSION V: Mechanical Circulatory Support  
Moderators: Goro Matsumiya (Chiba, Japan), Cumaraswamy Sivathasan (Singapore) | SESSION VI: Pulmonary Hypertension and The Right Heart  
Moderators: Edmund M. T. Lau (Sydney, Australia), Kevin K. H. Kam (Hong Kong), Toi Meng Mok (Macau), Yuichi Tamura (Tokyo, Japan) |
| 15:40 - 15:50   | LVAD implantations in Hong Kong  
Cally K. L. Ho (Hong Kong) | The Hemodynamic Characteristics Of Severe Chronic Lung Disease Referred For Lung Transplantation In Hong Kong  
Michael K. L. Wong (Hong Kong) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50 - 16:00</td>
<td>Destination Therapy (Durable) LVAD Program at Chiba University Hospital and in Japan</td>
<td>Hiroki Kohno (Chiba, Japan)</td>
</tr>
<tr>
<td></td>
<td>Recent controversies in initiation of drug therapy for pulmonary arterial hypertension</td>
<td>Edmund M. Lau (Sydney, Australia)</td>
</tr>
<tr>
<td>16:00 - 16:10</td>
<td>Impact of Change in UNOS Priority Listing on VAD Implantation at Keck Hospital of USC: A Perspective from Los Angeles, California</td>
<td>Michael W. Fong (Los Angeles, USA)</td>
</tr>
<tr>
<td></td>
<td>Epidemiology and Disease Management of Pulmonary Hypertension During The Last Two Decades in Japan</td>
<td>Yuichi Tamura (Tokyo, Japan)</td>
</tr>
<tr>
<td>16:10 - 16:20</td>
<td>Roundtable Discussion</td>
<td>Roundtable Discussion</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>Tea Break</td>
<td></td>
</tr>
<tr>
<td>16:40 - 17:20</td>
<td>SESSION VII: Diabetic Cardiomyopathy</td>
<td>SESSION VIII: Cardiac Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Moderators: Mónica Pon (Macau), Juliana C. N. Chan (Hong Kong), Alice P. S. Kong (Hong Kong)</td>
<td>Moderators: Lucky R. Cuenza (Philippines), Ngai-Yin Chan (Hong Kong)</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>miR-320 and Diabetic Cardiomyopathy</td>
<td>Cardiac Rehab Program at National University Heart Centre, Singapore</td>
</tr>
<tr>
<td></td>
<td>Dao Wen Wang (Wuhan, China)</td>
<td>Tee Joo Yeo (Singapore)</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>Human Induced Pluripotent Stem Cell Modelling for Diabetic Cardiomyopathy and its Susceptibility to SARS-CoV2 myocardial damage</td>
<td>Updates on the Progress and Development of Cardiac Rehabilitation in Asia</td>
</tr>
<tr>
<td></td>
<td>David C. W. Siu (Hong Kong)</td>
<td>Ngai-Yin Chan (Hong Kong)</td>
</tr>
<tr>
<td>17:00 - 17:10</td>
<td>Optimal Management of Glucose and Extraglycemic Risks in Patients with Heart Failure and Diabetes</td>
<td>Cardiac Rehab Program at CUHK Medical Centre</td>
</tr>
<tr>
<td></td>
<td>Andrea O. Y. Luk (Hong Kong)</td>
<td>Eva Y. W. Chun (Hong Kong)</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>Roundtable Discussion</td>
<td>Roundtable Discussion</td>
</tr>
<tr>
<td>17:20 - 18:00</td>
<td>SESSION IX: Cardiorenal Interactions</td>
<td>SESSION X: Palliative Care</td>
</tr>
<tr>
<td></td>
<td>Moderators: Narittaya Varothai (Bangkok, Thailand), Ling Ling Ip (Hong Kong), Ka Lung Chui (Hong Kong)</td>
<td>Moderators: Huei Yaw Wu (Singapore), Raymond S. K. Lo (Hong Kong), Tung Wai AuYeung (Hong Kong)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>17:20 - 17:30</td>
<td>The Cardiorenal Axis, A Love-hate Relationship: Can Manipulating The Kidney Affect The Heart?</td>
<td>Marjorie W. Y. Foo (Singapore)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interethnic Differences in Advance Care Planning for End-Stage Heart Failure: Practice Tips from Singapore</td>
</tr>
<tr>
<td>17:30 - 17:40</td>
<td>Diabetic Cardiomyopathy and Nephropathy: Lessons from The Hong Kong Diabetes Register</td>
<td>Ronald C. W. Ma (Hong Kong)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Managing Frailty in End-Stage Heart Failure</td>
</tr>
<tr>
<td>17:40 - 17:50</td>
<td>Intensive Volume Removal in Patients with Advanced Heart Failure and Chronic Kidney Disease: Pitfalls and Pearls</td>
<td>Narittaya Varothai (Bangkok, Thailand)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inotropic Support for End-Stage Heart Failure in the Ambulatory Setting</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Roundtable Discussion</td>
<td>Roundtable Discussion</td>
</tr>
</tbody>
</table>
Biography of Guest of Honour

Hong Fung

Dr. Hong FUNG is the Executive Director and Chief Executive Officer of the CUHK Medical Centre (CUHKMC). CUHKMC is a private teaching hospital wholly owned by The Chinese University of Hong Kong (CUHK).

Dr. FUNG is also a Professor of Practice in Health Services Management at the Jockey Club School of Public Health & Primary Care, CUHK, where he teaches health services planning, healthcare innovation and technology management, healthcare financing, communications and marketing, and decision making in the School’s master and leadership programs.

Before he joined CUHK in 2014, Dr. FUNG was Cluster Chief Executive of the New Territories East Cluster and Hospital Chief Executive of the Prince of Wales Hospital at the Hospital Authority (HA) from 2002 to 2013, overseeing the management and operations of 7 public hospitals.

Prior to that, he worked in the HA Head Office and was responsible for the planning and development of the public hospital services and facilities for over a decade. He spearheaded the development of HA’s Clinical Management System and electronic patient records.

Dr. FUNG was President (2014-2018) and Chief Censor (2010-2013) of the Hong Kong College of Community Medicine. Dr. FUNG is well recognized for his expertise in medical leadership, health planning, health informatics, and health services management.
James C. Fang

James Chen-Tson Fang is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.

Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women's Hospital/Harvard Medical School.

His first faculty appointment was at the Brigham and Women’s Hospital/ Harvard Medical School in 1997. In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. He also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine. In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.

Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.

Biography of Keynote Speaker
Biography of Distinguished Professorial Lecturer

Cecilia W. Y. Lo

Prof. Cecilia Lo is the Distinguished Professor and Chair of the Department of Developmental Biology at the University of Pittsburgh School of Medicine. She has longstanding interest in the genetics of congenital heart disease (CHD), having conducted the largest mouse mutagenesis screen for CHD that uncovered a central role for cilia biology in CHD pathogenesis. Her screen also recovered the first model of hypoplastic left heart syndrome (HLHS), demonstrating an obligate multigenic etiology. Leveraging findings in mice, she also pursued clinical translational studies with patients’ induced pluripotent stem cells to investigate acute early heart failure and clinical outcomes in HLHS.

Biography of Overseas Speakers (by alphabetical order)

Antoni Bayés-Genís

Prof. Bayés-Genís gained his medical degree from Barcelona Autonomous University, before specializing in cardiology at the ‘Santa Creu i Sant Pau’ Hospital in Barcelona and becoming the Head of the Heart Failure Unit there. Prof. Bayés-Genís’ research focuses on precision medicine using novel biomarkers for diagnosis, prognosis, monitoring and guided-therapy in heart failure and he was involved in the characterization of natriuretic peptides, ST2 and high sensitivity cardiac troponin T for clinical use. He is currently board member of the HFA, and Chair of the 2022 HFA Congress. Prof. Bayés-Genís is well published in the medical literature, with more than 700 articles published in international peer-reviewed journals.
Chiara Bucciarelli-Ducci

Dr. Bucciarelli-Ducci is a consultant cardiologist and imaging specialist at the Royal Brompton and Harefield Hospitals, Guys' and St Thomas NHS Trust in London, United Kingdom. She is also an honorary Senior Lecturer in the School of Biomedical Engineer and Imaging Sciences at King’s College London. She previously developed and led the Cardiac MRI Unit of the Bristol Heart Institute, University Hospitals Bristol and Weston NHS Trust, Bristol, United Kingdom (2010-2021) as a honorary consultant cardiologist and senior lecturer at the University of Bristol, UK. She was awarded a PhD in Cardiac Magnetic Resonance at the National Heart and Lung Institute, Imperial College London (2012) and was a senior clinical and research fellow at the Royal Brompton Hospital, London, UK (2006-2010).

She is the Chief Executive Officer (CEO) of the Society for Cardiovascular Magnetic Resonance (SCMR) since 2019, and past Vice-President and past chair of the cardiac MRI section (2016-2018) of European Association of Cardiovascular Imaging (EACVI), European Society of Cardiology (ESC). She was part of the writing committee for the 2017 ESC guidelines on STEMI and the 2018 ESC/AHA/ACC/WHF 4th definition of myocardial infarction, and authored numerous EACVI position papers.

She is a consultant for the International Atomic Energy Agency (IAEA) (for medical imaging) of the United Nations and a consultant for the European Medicines Agency (EMA) (for MRI contrast agents) of the European Union.

Since 2020 she is one of the deputy editors for European Heart Journal with responsibility for the imaging section. In addition, she is an editorial consultant for JACC Cardiovascular Imaging and in the editorial board of Circulation Imaging and of the European Heart Journal- Cardiovascular Imaging. She is a reviewer for all major cardiology and imaging journals and a passionate educator and advocate on the use of non-invasive imaging, particularly cardiovascular magnetic resonance, to improve patients’ management and prognosis.

Yang Hyun Cho

Dr. Cho completed undergraduate training at Korea University in 2001 and completed training as a thoracic and cardiovascular surgeon in 2006. He is currently a director of the Adult ECMO Service and a surgical director of Heart Transplantation and Mechanical Circulatory Support Service at Samsung Medical Center. He holds an Associate Professor appointment in the Sungkyunkwan University School of Medicine. He is a leading physician and surgeon of LVAD in Korea. He is also active in research in extracorporeal circulation, ventricular assist devices, aortic surgery, and cardiac transplantation. He has published more than 140 articles.
Jennifer A. Cowger
Dr. Cowger is the medical director of the Henry Ford Hospital MCS program and cardiac critical care unit. She is an active member of ISHLT, the Heart Failure Society of America, and the American College of Cardiology. She is also the Deputy Editor for JHLT. She have over 150 publications and has participated in several guidelines and consensus documents. Her research interests include MCS/shock, sarcoid, and cardiorenal syndrome.

Filippo Crea
Professor Filippo Crea is Director of the Department of Cardiovascular and Pneumological Sciences and Director of the Postgraduate School in Cardiology the Catholic in Rome. He is Editor-in-Chief of the “European Heart Journal” (2020). He is Fellow of the American College of Cardiology and of the European Society of Cardiology. In 1992 he received from Professor Rita Levi Montalcini the Newburg Prize for his scientific contribution to the cardiovascular research. In 2013 he received the Recordati International Prize for achievement in researching the pivotal role of microcirculation in systemic and organ diseases. He is author of more than 1500 publications.

Mark H. Drazner
Dr. Mark H. Drazner, an advanced heart failure/transplant cardiologist, is the Clinical Chief of Cardiology at UT Southwestern Medical Center. His research interests focus on left ventricular hypertrophy as an intermediate phenotype in the progression to cardiac failure, as well as the utility of the clinical examination in management of patients with heart failure. In 2020 he received the Patricia and William L. Watson Jr., M.D. Award for Excellence in Clinical Medicine, the highest honor in clinical care offered at UT Southwestern Medical Center. He currently is the President of the Heart Failure Society of America.
**Biography of Overseas Speakers** (by alphabetical order)

**Gregg C. Fonarow**
Gregg C. Fonarow is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA. He serves as Chief of the UCLA Division of Cardiology (Interim), Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-Director of UCLA’s Preventative Cardiology Program. His research interests center on acute and chronic heart failure, preventative cardiology, quality of care, outcomes, and implementing treatment systems to improve clinical outcomes. Dr. Fonarow has published over 1400 research studies and clinical trials in heart failure, disease management, preventative cardiology, and outcomes research. Each year 2014 to 2020, Dr. Fonarow has been selected by Clarivate for the list of Highly Cited Researchers. In 2020, Dr. Fonarow became a Member of the Association of University Cardiologists. This organization was founded in 1961 and is only limited to an active membership of 135 academic cardiologists from the United States, elected by their peers.

**Michael W. Fong**
Dr. Fong is Associate Professor of Clinical Medicine at the University of Southern California with 15 years of experience performing clinical work and research in heart failure, cardiac transplantation, mechanical circulatory support, cardiac MRI and hypertension. He is Director of Heart Failure at Los Angeles County + USC Medical Center, and co-founded the Advanced Heart Failure and Cardiomyopathy Program at Keck Medical Center of USC in 2011. He was Associate Cardiology Fellowship Program Director from 2016-2018. He has published 42 articles and 4 book chapters, and is the site principal investigator on 8 industry-sponsored clinical trials, and one investigator-initiated project.

**Marjorie W. Y. Foo**
Prof. Foo graduated from the Queens University Belfast, UK 1989, and trained as a nephrologist in University College London Hospital and Hammersmith Hospital. Currently working in Singapore General Hospital as a senior consultant since 2002. She was the head of renal medicine department from 2014-2020. She is also part-time consultant for the Ministry of Health Singapore, assisting in national projects to retard chronic kidney disease (HALT-CKD) as well as project to improve peritoneal dialysis (PD) patients’ quality of life through the provision of national home visit support. Research interest is in quality of life in CKD patients and device innovation for dialysis.
Navin K. Kapur

Dr. Kapur is an Associate Professor in the Department of Medicine and Division of Cardiology. He is the Executive Director of the CardioVascular Center for Research and Innovation, Director of the Acute Circulatory Support Program, Director of the Interventional Research Laboratory, and Director of the Cardiac Biology Research Center at Tufts Medical Center. He is a dual, board-certified Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist. His clinical expertise focuses on invasive hemodynamics, mechanical circulatory support, complex percutaneous coronary intervention, and interventional therapies for patients with advanced heart failure. He has mentored over 15 post-doctoral national and international trainees and directs a program for junior faculty & senior fellow development within the CVCRI. He developed the first combined Interventional Heart Failure Clinical Fellowship at Tufts Medical Center with over 10 graduates and funding through 2023.

Dr. Kapur’s clinical research focuses on mechanical support and heart failure. He is the Founder & Executive Director of the National Cardiogenic Shock Working Group which includes over 20 centers in the United States. He serves as Principal Investigator for several active trials in mechanical circulatory support including Impella Expandable CP EFS trial, the SHIELD-II HeartMate Percutaneous Heart Pump Trial and the STEMI-Door-to-Unload Trial. He serves on committees involved with the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, the Society for Cardiac Angiography and Interventions, the Cardiovascular and Structural Interventions, & the European Society of Cardiology.

Dr. Kapur’s translational research focuses on preclinical models of acute and chronic heart failure, invasive hemodynamics, circulatory support device development, & cardioprotective mechanisms in the setting of acute myocardial infarction. His laboratory identified first that acute mechanical unloading of the left ventricle activates a cardioprotective signaling program in the setting of acute myocardial infarction and the first to identify novel molecular mechanisms regulating biventricular function with veno-arterial and veno-veno extracorporeal membrane oxygenation.

Dr. Kapur is the inventor on multiple patents focused on device and drug therapy development. He co-founded and serves head of the scientific advisory board for preCARDIA, an award-winning device-based company focused on cardio-renal unloading for heart failure. He has extensive experience working with venture capital firms, start-up companies, and strategic industry partners.
Biography of Overseas Speakers (by alphabetical order)

**Hiroki Kohno**

Hiroki Kohno is a senior assistant professor of cardiovascular surgery at Chiba University Graduate School of Medicine and a staff surgeon at Chiba University Hospital, Japan. After completing his surgical training at multiple university-affiliated centers, Dr. Kohno pursued his fellowship training at The Alfred Hospital, Melbourne, Australia, where he participated in over a hundred adult heart transplant cases, before joining the current cardiovascular staff in 2010. His main interests are advanced heart failure treatments, including mechanical circulatory support and transplantation, and development of a novel cardioprotective agent using cytokines, such as interleukin-11.

**Edmund M. Lau**

Edmund Lau is an academic respiratory physician working at Royal Prince Alfred Hospital, Sydney and Associate Professor of Medicine at the University of Sydney. He is the lead Respiratory Physician of the Pulmonary Hypertension Service at Royal Prince Alfred Hospital. He is the Medical Director of the Australian and New Zealand Pulmonary Hypertension Registry. He has authored more than 100 peer-reviewed publications, mostly on the topic of pulmonary hypertension.

**Peter S. Macdonald**

Prof. Macdonald is the Medical Director of the Cardiopulmonary Transplant Unit at St Vincent’s Hospital in Sydney, Conjoint Professor of Medicine in the University of New South Wales, and Co-head of the Transplantation Research Laboratory at the Victor Chang Cardiac Research Institute. Prof. Macdonald has a special interest in heart failure, pulmonary hypertension, heart transplantation, donor management, and organ preservation and transplant rejection. He has established a basic research laboratory at the Victor Chang Institute and has been involved in numerous clinical studies which mostly focused on the translation of laboratory findings into clinical practice. Outside of his roles in Sydney, Peter has been flying out to the Condobolin Aboriginal Medical Centre to provide specialty services to the community for over fifteen years.
**Mandeep R. Mehra**

Dr. Mehra is the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine, a Professor of Medicine at Harvard Medical School and Executive Director of the Center for Advanced Heart Disease at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. He also served as founding Medical Director of the Heart and Vascular Center (2013-2019) at the Brigham and was Editor-in-Chief, The Journal of Heart and Lung Transplantation, which rose to #1 ranked journal in its field under his leadership (2010-2020). Dr. Mehra is the only individual to have been appointed as President (2008) of the International Society of Heart and Lung Transplantation (ISHLT) and President of the Heart Failure Society of America (HFSA), the two premier societies in the field of advanced heart disease. He has authored over 500 scholarly papers with a specific focus on Advanced Heart Failure and among some highlights, discovered the obesity paradox in heart failure, described the natural history of cardiac allograft vasculopathy after transplantation, established the pivotal international guidelines for selection and care of transplant patients, defined the role of new immunosuppression to improve transplant outcomes and helped introduce genomic based biomarkers for evaluating cardiac allograft rejection. In recent years his research focus shifted to evaluation of novel left ventricular assist devices (“artificial heart pumps”) engineered to reduce the burden of adverse effects and allow use in broader populations of patients. This work published in the New England Journal of Medicine has resulted in the introduction of novel therapy for advanced heart failure patients and its practice changing implications have been seen around the world in advanced heart failure. Dr. Mehra has a certificate in Executive leadership from the Harvard Business School and also completed a Master of Science in Health Economics and Management at the London School of Economics in 2018, a degree earned through his designation as a “Braunwald Scholar”.

---

**Shirlyn H. S. Neo**

Dr. Neo graduated from the National University of Singapore in 2007 and obtained her MRCP (UK) and MMed (Internal Med) in 2010. She joined the Division of Supportive and Palliative Care, National Cancer Centre Singapore since November 2015. Alongside clinical work, Dr. Shirlyn Neo is also interested in the educational activities of physicians, nurses, and allied health. She believes strongly in the value of research. She won a Ministry of Health-Health Services Research New Investigator Grant in 2021 for a pilot randomized controlled trial investigating the impact of a nurse-led model of supportive care for heart failure patients and their caregivers.
Biography of Overseas Speakers (by alphabetical order)

Sunita Puri

Dr. Sunita Puri is an Associate Professor of Medicine at USC, where she has served as the Medical Director of the Palliative Medicine Service at Keck Hospital and Norris Cancer Center of the University of Southern California, where she also serves as Chair of the Ethics Committee. Sunita is the author of That Good Night: Life and Medicine in the Eleventh Hour, a critically acclaimed literary memoir examining her journey to the practice of palliative medicine, and her quest to help patients and families redefine what it means to live and die well in the face of serious illness. Sunita received writing residencies at the MacDowell Colony, UCross Foundation, and Mesa Refuge, and was a finalist for the PEN Center's Emerging Voices Writing Fellowship. The recipient of a Rhodes Scholarship, her writing has appeared in the New York Times, the Los Angeles Times, Slate, and the Journal of the American Medical Association. In 2018, she was awarded the Etz Chaim Tree of Life Award from the USC School of Medicine, awarded annually to a member of the faculty who, in the eyes of the campus community, models and provides humanistic and compassionate care.

Sandeep Seth

Dr. Sandeep Seth is a professor in Cardiology in All India Institute of Medical Sciences (AIIMS) Delhi. He is the professor in charge of Heart Failure and Transplant Services in AIIMS Delhi. His research in heart failure, stem cells, heart failure imaging, yoga, exercise and rehabilitation and heart failure clinics and nursing and transplantation. He has research grants from ICMR, DBT, DST, CSIR, NIH, UKIERI, with more than 200 publications and he is the editor in chief of Journal of Practice of Cardiovascular Sciences.
Ching Hui Sia
Dr. Sia received his medical training from the National University of Singapore and Internal Medicine Chief Residency and Cardiology Senior Residency at the National University Health System. He later obtained the Membership of the Royal College of Physicians of the United Kingdom, Master of Medicine in Internal Medicine, and Master of Clinical Investigation. He is an Associate Consultant at the National University Heart Centre Singapore and a Senior Lecturer at the National University of Singapore. Dr. Sia’s clinical and research interests involve using multi-modality cardiac imaging to investigate mechanisms of disease, diagnose, prognosticate, and guide management of patients. He has a special interest in Cardio-Neurology and cardiomyopathies. He won several research grants thus far and published more than 140 PubMed-indexed papers in peer-reviewed journals to date.

Lynne Warner Stevenson
Lynne Warner Stevenson has been Director of Cardiomyopathy at UCLA, Brigham and Women’s Hospital in Boston, and currently Vanderbilt University. She has contributed to over 30 guidelines for heart failure (HF), transplantation, rhythm devices, and advanced decision-making. She has served on the FDA and as associate editor for Circulation, Circulation: Heart Failure and JACC. She has played leadership roles in NHLBI trials ESCAPE, REMATCH and the HF Network, and as a designer of the NCDR ICD registry and NHLBI INTERMACS registry and the REVIVAL cohort of less-sick patients considered for LVADs. Her physiologic research has focused on taking the congestion out of HF, profiling end-stage HF for advanced therapies, and personalizing therapies for cardiomyopathy. Her newest interest is learning how genetic variants influence trajectories of cardiomyopathy. She co-chaired the recent ACC Pathway for HF hospitalization, will be a co-chair for the upcoming NHLBI Workshop on Advanced Heart Failure and was awarded the Lifetime Achievement Award by Heart Failure Society of America in 2021. Strong commitments for her remain training to sustain the patient-clinician connection, re-defining HF without congestion, and seeking clarity to personalize care for quality and length of life.
Biography of Overseas Speakers (by alphabetical order)

Yuichi Tamura

Prof. Tamura is Prof. Tamura completed his medical training at Keio University, Tokyo, Japan and his residency as a fellow of pediatrics at the Mitsui Memorial Hospital, Tokyo. Prior to his current position, he was an assistant professor in the Advanced Pulmonary Hypertension Treatment Department at Keio University School of Medicine and senior lecturer at the Department of Cardiology, International University of Health and Welfare. He also completed a postdoctoral fellowship at the University of Paris-Sud, France with Marie Curie research fellowships from European Union.

Prof. Tamura is the director of national PH registry (Japan PH Registry) in Japan. And he is a task force member of World Symposium on Pulmonary Hypertension Association (WSPHA), and a member of Task Force 6: Risk Stratification and Medical Therapy of PAH in 6TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION (2018 Nice). He is a fellow of the European Society of Cardiology as well as a member of their Pulmonary Circulation and Right Heart Function committee, and scientific assembly member of the Japanese Respiratory Society’s Pulmonary Circulation and Lung Injury committee. He also serves on the associate editor of International Journal of Cardiology, European Heart Journal Case Report and European Respiratory Review. And he is a section editor of JACC Asia.

Nancy K. Sweitzer

Nancy K. Sweitzer, MD, PhD, director of the University of Arizona Sarver Heart Center and professor of medicine is board-certified in advanced heart failure and transplant. Internationally recognized for her leadership in research and clinical trials, Dr. Sweitzer is a co-director of the Graduate Program in Clinical Translational Sciences. Dr. Sweitzer is chair of the Clinical Trials Study Section of the NHLBI. She is editor-in-chief of the journal, Circulation: Heart Failure, past-president of the Association of Professors of Cardiology and on the Board of Directors for the Heart Failure Society of America.
**W. H. Wilson Tang**

Dr. Tang is Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. As a graduate from Harvard Medical School and received postdoctoral training at Stanford University and the Cleveland Clinic, Dr. Tang is a heart failure/transplant cardiologist that specialized in cardiomyopathies. He is currently leading early-phase clinical trials in novel drug and device trials in cardio-renal diseases targeting novel disease pathways. Dr. Tang has published over 700 peer-reviewed scientific manuscripts and book chapters (h-index 94) and has been elected as member of the American Society of Clinical Investigation in 2013 for his contributions to physiologic and mechanistic understanding of cardio-renal syndromes, and the Association of American Physicians in 2018 for identifying the contributing role of diet and microbiome in cardiovascular diseases.

---

**Nir Y. Uriel**

Prof. Nir Uriel is the Director of New York Presbyterian Heart Failure, Heart Transplant and Mechanical Circulatory Support Programs and the Director of those programs at Columbia University. In the past, he was Chair of the Mechanical Circulatory Support Council of the International Society of Heart and Lung Transplantation (ISHLT, Chair 2017-2019, Past Chair 2019-2021). His contribution to scientific literature includes more than 230 peer-reviewed publications. His research focus is on heart failure physiology, heart transplant and mechanical circulatory support. With the support of an NIH K23 grant, he studied the metabolic changes in advanced heart failure and the effect of LVAD therapy on metabolic profile of these patients. During that time, he also completed a MSc degree in Biostatics at the Mailman School of Public Health. Prof. Uriel has also developed and validated multiple algorithms for treatment of patients supported with mechanical assist devices and the ramp test for speed adjustment. An algorithm based on the association of speed changes on left ventricular size and hemodynamics has become a common clinical test among the HF community. A significant amount of his research is devoted to mechanical circulatory support, including the RAMP-IT-UP and RAMP IT UP 2 studies, combining LVAD and CardioMEMS.
**Biography of Overseas Speakers** *(by alphabetical order)*

**Narittaya Varothai**

Narittaya Varothai, MD graduated of Phramongkutklao College of Medicine in Bangkok, Thailand. She completed internal medicine residency at St. Elizabeth Health Center in Ohio, where she was selected chief resident and received the resident of the year award. Subsequently, she finished her nephrology fellowship training at Tufts University in Boston. With keen interested in taking care of the elderly patients, she completed fellowship in geriatric medicine at Massachusetts General Hospital, Harvard University. Currently, she works at the Phramongkutklao Hospital as a combined geriatrician and nephrologist where she can integrate holistic care to the elderly and kidney disease patients.

**Yan Wang**

During the past decade, Prof. Yan Wang of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China has mainly focused on the following research areas: zero-fluoroscopic ablation of arrhythmia in more than 2000 cases, signal transduction of β-adrenergic receptor in ventricular arrhythmia, and high power and medium duration ablation of atrial fibrillation with 60 Watt in over 500 cases. He has been a PI in clinical research concerning three-dimensional navigated Pulse Field Ablation. He is also the editor of the textbook, Cardiac Electrophysiology Without Fluoroscopy (Springer Nature, 2019), and an editorial board member of the Pacing and Clinical Electrophysiology (PACE) journal.
Dao Wen Wang

Prof. Dao Wen Wang obtained his Ph.D. in Cardiology from Tongji Medical University (1992), and did post-doctoral study with Dr. Capdevila in Vanderbilt University. He is the Chief of Department of Internal Medicine and Division of Cardiology at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, and is the Director of Translational Medicine Center & Genetic Diagnosis Center and Institute of Hypertension. He is also Chairman of ISHR Chinese Section Translational Medicine Council, and Chairman of Internal Medicine Section of Medical Association of Hubei Province. Dr. Wang works on studying both clinical and basic issues in cardiology, and promoting evidence-based medicine and standardized treatment protocols in clinical practice. He especially contributes to the diagnosis and treatment of hypertension, and fulminant myocarditis, as well as genetic diagnosis and personalized medicine.

Tee Joo Yeo

Assistant Professor Yeo Tee Joo is a Senior Consultant with the Department of Cardiology at the National University Heart Centre, Singapore and heads its Cardiovascular Prevention and Rehabilitation unit. He is a WHO Ischaemic Heart Disease Rehabilitation 2030 Development Group Member, the Singapore representative for the International Council for Cardiovascular Prevention and Rehabilitation and a Member of the Board of Directors of the Singapore Heart Foundation.


Biography of Hong Kong Speakers (by alphabetical order)

Ngai-Yin Chan

Dr Ngai-Yin Chan is currently Chief-of-Service and Consultant Physician in the Department of Medicine & Geriatrics in Princess Margaret Hospital and North Lantau Hospital. He is also an Honorary Clinical Associate Professor of the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is the Immediate Past President of the Hong Kong College of Cardiology. He is the Co-chairman of the Asian Preventive Cardiology and Cardiac Rehabilitation Conference. His research interest is on catheter cryoablation, epidemiology and community screening of atrial fibrillation, ICD and pacing therapy, left atrial appendage occlusion, preventive cardiology and cardiac rehabilitation.

Eva Y. W. Chun

Ms. Chun has gained a wide-range of clinical experience in rehabilitation from various renowned hospitals from Singapore to Hong Kong. During her years in Hong Kong, she was once the team leader and coordinator of the cardiac rehabilitation program in the Physiotherapy Department, Prince of Wales Hospital, Hong Kong. Cardiac rehabilitation is one of her interested areas, thus she has devoted herself as the executive committee member of the Cardiopulmonary Specialty Group, Hong Kong Physiotherapy Association since 2006. Currently Ms. Chun is a Principal Physiotherapist of CUHK Medical Centre, which commenced its service in 2021. She is the leader of the physiotherapy team tasked with starting up the cardiac rehabilitation program in CUHK Medical Centre.
**Erik Fung**

Dr. Fung is a medical graduate of CUHK and a board-certified cardiologist specializing in advanced heart failure. He is also certified by the National Board of Echocardiography (US), and the Heart Failure Association of the European Society of Cardiology. Following internship at Prince of Wales Hospital, Hong Kong, he went on to study for a PhD in immunogenetics and immune tolerance at University of Cambridge, UK. Thereafter he completed internal medicine residency in Boston, cardiovascular medicine fellowship at Dartmouth-Hitchcock Medical Center, New Hampshire, and advanced fellowship in heart failure/transplant cardiology at the Keck Hospital of USC, Los Angeles, California. In 2016, he was appointed Assistant Professor (Clinical) in the Department of Medicine & Therapeutics, CUHK. He is a clinician-scientist in the Li Ka Shing Institute of Health Sciences, and principal investigator of the Laboratory for Heart Failure + Circulation Research (LHFCR), CUHK. His research interests include heart failure and frailty, inflammation and aging (inflammaging), mechanical circulatory support, and pulmonary hypertension. His laboratory is actively working on projects aiming to elucidate pathophysiological mechanisms of heart failure precursors (UFO study), acute decompensated heart failure (AHF study), and arrhythmias in frail older adults with diabetic cardiomyopathy (HARE study). His research group has developed expertise in metabolomic and epigenetic analyses. He is a member of the Hospital Authority's Heart Failure Working Group, and has served as an expert on the HA Safe Introduction of New Procedure/Technology (HAMSINP) panel. He was formerly an Associate Editor of *Heart Asia*. He is an editorial board member of the International Journal of Cardiology, and regularly reviews for European Heart Journal, European Journal of Preventive Cardiology, Circulation: Heart Failure, Journal of American Heart Association, JACC: Asia, and other major cardiology journals. He is a Section Leader for an ISHLT consensus document on frailty in advanced heart failure that will be published later this year.

**S. H. Jo Jo Hai**

Dr. Jo Jo Hai graduated from the University of Hong Kong. She received her cardiology training in the Queen Mary Hospital in Hong Kong and cardiac electrophysiology training in the Mayo Clinic, Rochester, Minnesota, USA. After completion of training, she served in Queen Mary Hospital and the University of Hong Kong as a clinical assistant professor. Recently, she has also begun her practice in Glenegales Hospital. Her major research and clinical interest include arrhythmia intervention, device implantation and heart failure management.
Biography of Hong Kong Speakers (by alphabetical order)

**Cally K. L. Ho**

Dr Cally Ho is the Consultant Cardiac Surgeon currently working in Department of Cardiothoracic Surgery of Queen Mary Hospital, Hong Kong. Dr Ho obtained her degree of Bachelor of Medicine and Bachelor of Surgery in year 2000, and she obtained her Master of Medical Sciences in year 2011 from The University of Hong Kong. She had her cardiothoracic surgical training in Grantham Hospital, Hong Kong since year 2004 and obtained her Fellowship in Cardiothoracic Surgery from The Royal College of Surgeons of Edinburgh and The College of Surgeons of Hong Kong in year 2008. Afterwards she went to Papworth Hospital in United Kingdom to specialised her training in Heart & Lung Transplantation and ventricular assist device. Her special interests are heart transplantation, lung transplantation, ventricular assist device, mechanical circulatory support, aortic surgery and complex redo valve surgery. She is actively involved in the aortic registry and also in the development of heart & lung transplantation & VAD programs in the department.

**Andrea O. Y. Luk**

Andrea Luk is currently the Associate Professor of the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. She is also the Medical Director (Non-Oncology) of the Phase 1 Clinical Trial Centre and serves as an honorary associate consultant at the Prince of Wales Hospital. Dr Luk completed her specialist training in endocrinology, reproduction and metabolism in 2007. Her research interests include epidemiology of diabetes and diabetes-related complications, young-onset diabetes, as well as translational studies of care models in people with diabetes. She has received multiple competitive grants to explore the aetiology and pathophysiological mechanisms underlying diabetes in young people. She has been an investigator of over 100 clinical trials. She has published more than 130 articles in peer-reviewed journals and has led the section on type 2 diabetes in youth in the 2021 edition of the International Diabetes Federation Atlas.
**Ronald C. W. Ma**

Ronald Ma is a clinician-scientist and a specialist in Endocrinology, Metabolism and Diabetes. Dr Ma’s research focuses on the epidemiology and genetics of diabetes and its complications, gestational diabetes, polycystic ovary syndrome, and the developmental origins of diabetes. He is currently leading a multi-disciplinary project team to leverage on the large Hong Kong Diabetes Register and accompanying biobank to identify novel molecular markers for diabetic complications, and is the principal investigator of the newly established Hong Kong Diabetes Biobank. He has also been involved in numerous multi-centre randomized clinical trials on new treatments for type 2 diabetes. He has published over 350 research articles in international peer-reviewed journals and has received several awards. He is serving as co-chair of the Precision Prognostics in Type 2 Diabetes Workgroup in the American Diabetes Association Precision Medicine in Diabetes Initiative (PMDI), and led the workgroup on Type 1 Diabetes in Adults for the IDF Diabetes Atlas (10th edition). He is a past regional Editor of Diabetic Medicine, and currently serves as associate editor of Diabetologia, editorial board member of PLoS Medicine, Obesity Reviews, and Journal of Diabetes Investigation.

**Kin Shing Lun**

Dr. Kin Shing Lun graduated from the Faculty of Medicine of the University of Hong Kong in 1987. Currently he is the consultant and service head of the Division of Pediatric Cardiology of the Department of Pediatrics in the Hong Kong Children’s Hospital. He is the honorary clinical associate professor of the Department of Pediatrics & Adolescent Medicine of the University of Hong Kong. Apart from his subspecialty interests in pediatric mechanical circulatory support, pulmonary hypertension and pediatric heart transplantation, his other subspecialty interests include diagnostic and interventional catheterization of congenital heart diseases.
**Biography of Hong Kong Speakers** *(by alphabetical order)*

**David C. W. Siu**

Prof Siu is currently the Clinical Professor of the Department of Medicine at the University of Hong Kong. He obtained his medical degree (M.B., B.S.) in 1997 and Medical Doctor (M.D. with Sir Patrick Manson Gold Medal) in 2010 at the University of Hong Kong. His research interests focus on inheritable cardiac diseases, atrial fibrillation, and heart failure, as well as stem cell research for regenerative medicine. Notably, his laboratory is one of the first three laboratories worldwide to generate human induced pluripotent stem cells using an animal product-free protocol. To date, Siu has published a total of 150 peer-reviewed articles in international journals such as Lancet, Journal of the American Medical Association (JAMA), Archive of Internal Medicine, Circulation, Journal of American College of Cardiology, Blood, Stem cell, Diabetes Care, Journal of Metabolism and Clinical Endocrinology, and has contributed 12 book chapters in Cardiology and Stem Cell Biology.

**Michael K. L. Wong**

Dr. Michael Wong is one of the heart transplant, left ventricular assist device and extracorporeal membrane oxygenation physicians in the Cardiac Medical Unit, Grantham Hospital. Dr. Wong graduated from University of Hong Kong in 2005 and completed cardiology training in Queen Mary Hospital. He received ECMO training at National Taiwan University Hospital in 2010 and then received overseas training in advanced heart failure and transplantation at the Mayo Clinic, Rochester, Minnesota, USA. He is currently Associate Consultant in Grantham Hospital with clinical focus in advanced heart failure, mechanical circulatory support, heart transplantation as well as end-stage pulmonary arterial hypertension before lung transplantation.
Map & Exhibition

Charles K. Kao Auditorium, Hong Kong Science Park, Shatin, New Territories, Hong Kong
Acknowledgements

The Organising Committee would like to extend their heartfelt thanks to the following sponsors for their contributions and support to APAHFF 2022.

(in alphabetical order)

Abbott Medical (Hong Kong) Limited
AstraZeneca Hong Kong Limited
Bayer HealthCare Limited
Boehringer-Ingelheim Hong Kong Limited
Croucher Foundation
Eli Lilly Asia, Inc.
Novartis Pharmaceuticals (Hong Kong) Limited
Otsuka Pharmaceutical (Hong Kong) Limited
Pacific Medical Systems Limited
Philips Electronics Hong Kong Limited
PROTABOLIS LIMITED
Synmosa Biopharma (Hong Kong) Company Limited
Viatris Healthcare Hong Kong Limited
UNDERSTANDING HEARTMATE 3™ LEFT VENTRICULAR ASSIST DEVICE (LVAD) THERAPY

THE HEARTMATE 3™ LVAD SYSTEM

- A small implantable device that can help the heart pump blood
- Shown to reverse the symptoms of heart failure and improve survival and quality of life
- Helps heart failure patients return to enjoyable activities and active, full lives

1 HeartMate 3™ LVAD
2 Batteries
3 Modular Driveline
4 System Controller

PROVEN OUTCOMES AND EXCELLENT SAFETY PROFILE

SURVIVAL AT 2 YEARS
approaching that of heart transplantation

REVERSAL OF HEART FAILURE SYMPTOMS
from NYHA Class II/II to I or II at 6-months

79%

NYHA CLASS I
No symptoms or activity limitations

CLASS II
Slight activity limitations

CLASS III
Significant activity limitations

CLASS IV
Unable to carry on any physical activity without discomfort

Lowest published risks for continuous-flow LVAD

Stroke: 10%
Pump Thrombosis: 1%

THOUSANDS OF PATIENTS LIVE AN ACTIVE LIFE WITH THE HEARTMATE 3™ LVAD

“My life changed, for the better. I woke up refreshed. I woke up feeling like a million bucks.” — MARTHA

“Ever since I’ve had my HeartMate 3™, every day has been just amazing. I started biking at 10 weeks.” — DAVID

20,000+ patients worldwide have received the HeartMate 3™ LVAD

*92% 2-year survival for adult heart transplant patients between 2009 and 2015.
**For a continuous-flow LVAD in a randomized controlled trial.
***Any adverse events include pump thrombosis, stroke and gastrointestinal bleeding.

These materials are not intended to replace your doctor’s advice or information. For any questions or concerns you may have regarding the medical procedures, devices and/or your personal health, please discuss these with your physician.

Abbott
One St. Jude Medical Dr., St. Paul, MN 55127 USA, Tel 1 651 756 2000
Abbott.com

Abbott Medical (Singapore) Pte Ltd
2 Fraser Street #21-00 OUE Tower, Singapore 189952, Tel: 65 69148000
Registered under Act 717, MDA Registration Number: GD42372.7480

Abbott

© 2022 Abbott. All Rights Reserved.
MAT-2000446 V.3.0 Dam approved for Hong Kong, India, Indonesia, Malaysia, Philippines and Singapore use only.
For patients living with heart failure, Time is essential. So is starting with ENTRESTO.®

Make ENTRESTO your first choice in place of an ACE/ARB to help patients stay out of the hospital, live longer, and feel better right from the start.2,3

Change the heart. Change heart failure.4,5,11
Reverse cardiomyopathy, improve cardiac structure and function, and target HF via a unique dual MOA that inhibits neprilysin and RAAS

Provide the HF treatment superior to ACEi in all stages of the HFrEF patient journey.4,8
Your first choice in the hospital or outpatient setting, whether patients are newly diagnosed or have worsening symptoms

Make a lasting difference patients can feel.4,12
Help your patients stay out of the hospital, live longer, and feel better, so they have more time for what matters.

The Essential HF Intervention

ENTRESTO sacubitril/valsartan

ENTRESTO is endorsed by the 2021 ACC Expert Consensus on Stage C HFrEF patients

ENTRESTO is endorsed by NDA Expert Consensus on CVAE


In patients with HF who are at high risk for cardiovascular events (JAMA 2020;323:1557–1567), ENTRESTO significantly reduced the risk of cardiovascular death, hospitalization for HF, the composite of cardiovascular death or HF hospitalization, or the composite of cardiovascular death or urgent coronary revascularization (JAMA 2021;325:2290–2300; 2022;327:1031–1041).


In a substudy from the Leiden Heart Study (2017), patients receiving ENTRESTO were 43% less likely to have an index hospitalization for HF, or cardiac arrest, or sudden cardiac death (JAMA Cardiol. 2022;7:273–282).

The following statements are consistent with the most recent position statement of the American College of Cardiology Foundation/American Heart Association/Heart Failure Society of America (2013). The statements are based on the concept that important treatment goals for patients with heart failure include: decreasing risk of mortality; reducing risk of cardiovascular hospitalization; reducing the risk of structural heart failure progression; and improving quality of life.

In patients with HFrEF, ENTRESTO has been shown to significantly improve clinical outcomes when added to an ACE inhibitor (ACEi) (JAMA 2020;323:2047–2057; 2020;323:3009–3020; 2021;325:2290–2300; 2022;327:1031–1041; 2023;328:913–923).

In patients with HFpEF, ENTRESTO has been shown to significantly improve clinical outcomes when added to an ACEi (N. Engl. J. Med. 2021;384:1728–1738; 2022;386:2012–2025; 2023;388:1176–1188).

In patients with atrial fibrillation (AF), ENTRESTO significantly reduced the risk of stroke and other serious vascular events (JAMA Cardiol. 2021;6:1176–1188).

In patients with type 2 diabetes mellitus (T2DM) and stage C HFrEF, ENTRESTO significantly reduced the risk of death or HF hospitalization compared to placebo (Diabetes Care 2021;44:2263–2273).

In patients with prior history of MI or HF, ENTRESTO significantly reduced the risk of death or the composite of cardiovascular death, HF hospitalization, or emergency department visit for HF (JAMA 2020;323:1921–1931).

In patients with heart failure with preserved ejection fraction (HFpEF), ENTRESTO has been shown to significantly improve clinical outcomes when added to an ACEi (N. Engl. J. Med. 2021;384:1728–1738; 2022;386:2012–2025; 2023;388:1176–1188).

In patients with atrial fibrillation (AF), ENTRESTO significantly reduced the risk of stroke and other serious vascular events (JAMA Cardiol. 2021;6:1176–1188).

In patients with type 2 diabetes mellitus (T2DM) and stage C HFrEF, ENTRESTO significantly reduced the risk of death or HF hospitalization compared to placebo (Diabetes Care 2021;44:2263–2273).

In patients with prior history of MI or HF, ENTRESTO significantly reduced the risk of death or the composite of cardiovascular death, HF hospitalization, or emergency department visit for HF (JAMA 2020;323:1921–1931).

In patients with heart failure with preserved ejection fraction (HFpEF), ENTRESTO has been shown to significantly improve clinical outcomes when added to an ACEi (N. Engl. J. Med. 2021;384:1728–1738; 2022;386:2012–2025; 2023;388:1176–1188).

In patients with atrial fibrillation (AF), ENTRESTO significantly reduced the risk of stroke and other serious vascular events (JAMA Cardiol. 2021;6:1176–1188).

In patients with type 2 diabetes mellitus (T2DM) and stage C HFrEF, ENTRESTO significantly reduced the risk of death or HF hospitalization compared to placebo (Diabetes Care 2021;44:2263–2273).

In patients with prior history of MI or HF, ENTRESTO significantly reduced the risk of death or the composite of cardiovascular death, HF hospitalization, or emergency department visit for HF (JAMA 2020;323:1921–1931).

In patients with heart failure with preserved ejection fraction (HFpEF), ENTRESTO has been shown to significantly improve clinical outcomes when added to an ACEi (N. Engl. J. Med. 2021;384:1728–1738; 2022;386:2012–2025; 2023;388:1176–1188).

In patients with atrial fibrillation (AF), ENTRESTO significantly reduced the risk of stroke and other serious vascular events (JAMA Cardiol. 2021;6:1176–1188).

In patients with type 2 diabetes mellitus (T2DM) and stage C HFrEF, ENTRESTO significantly reduced the risk of death or HF hospitalization compared to placebo (Diabetes Care 2021;44:2263–2273).

In patients with prior history of MI or HF, ENTRESTO significantly reduced the risk of death or the composite of cardiovascular death, HF hospitalization, or emergency department visit for HF (JAMA 2020;323:1921–1931).